Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.48 USD | -4.41% | -4.49% | +118.25% |
May. 07 | Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating | MT |
May. 06 | Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M | MT |
Evolution of the average Target Price on Stoke Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Stoke Therapeutics, Inc.
Canaccord Genuity | |
TD Cowen | |
Wedbush | |
Needham & Co. | |
JPMorgan Chase | |
Cantor Fitzgerald | |
BofA Securities | |
Credit Suisse | |
HC Wainwright | |
Jefferies & Co. | |
UBS |
EPS Revisions
- Stock Market
- Equities
- STOK Stock
- Consensus Stoke Therapeutics, Inc.